Biocon FY26: ₹16,927 Cr revenue, ₹1,429 Cr profit

FY26 audited results: what the board approved

Biocon Limited said its board approved audited financial results for the fiscal year ended March 31, 2026, at a meeting held on May 7, 2026. The company reported consolidated revenue of ₹16,927 crore and consolidated net profit of ₹1,429.4 crore for FY26. Alongside the results, the board recommended a final dividend and cleared a proposal to raise Biocon’s stake in its material subsidiary, Biocon Biologics Limited (BBL). The company also announced a change in statutory auditors and disclosed several governance and leadership actions. These decisions matter for investors because they combine a full-year performance update with corporate actions tied to capital structure, consolidation, and oversight.

Key FY26 numbers reported across the disclosures

The text provided includes multiple consolidated revenue and profit figures for FY26 across different sections of the announcement. One section states consolidated revenue of ₹16,927 crore (₹1,69,270 million) and consolidated net profit of ₹1,429.4 crore (₹14,294 million). Another section states consolidated FY26 revenue of ₹15,261.7 crore (₹1,52,617 million) and net profit of ₹1,429.4 crore (₹14,294 million), and also mentions FY25 consolidated revenue of ₹13,001.7 crore (₹1,30,017 million) and FY25 net profit of ₹1,201.6 crore (₹12,016 million). A separate paragraph describes FY26 consolidated revenue of ₹16,927 crore compared with ₹15,261.7 crore in the previous year and cites FY26 consolidated net profit as ₹368.8 crore (₹3,688 million). Because these figures are presented within the supplied text without reconciliation notes, investors typically rely on the audited financial statements and accompanying notes filed with exchanges for the exact definitions and comparability.

Dividend: ₹0.50 per share, record date and payout window

Biocon’s board recommended a final dividend of 10%, amounting to ₹0.50 per equity share (face value ₹5) for FY26. The record date mentioned is July 3, 2026, to determine shareholder eligibility. The payout is scheduled on or before August 31, 2026, subject to shareholder approval at the Annual General Meeting. The 48th AGM is scheduled for August 6, 2026, according to the text. The dividend remains contingent on the necessary approvals, as highlighted in the disclosure.

BBL stake purchase: up to ~2% via preferential issue

A central board action was approval to acquire approximately 2% additional equity in Biocon Biologics Limited (BBL) for up to ₹330.73 crore through a preferential issue. The stated objective is to consolidate ownership and move BBL towards being a wholly owned subsidiary, including by purchasing shares from minority holders. Another section describes acquisition of remaining equity shares from employees and other shareholders via a share swap mechanism to support full integration. The preferential issue is described as issuance of up to 87,92,317 Biocon equity shares at an issue price of ₹376.16 per share. The completion of the BBL acquisition is targeted for June 30, 2026, with the note that delays in approvals could affect the integration timeline.

Governance updates: new auditors and board appointments

Biocon said M/s S. R. Batliboi & Associates LLP has been recommended/appointed as statutory auditors for a five-year term (2026-2031), succeeding the previous auditors. The disclosure also lists senior management personnel designations, including Dr. Anuj Goel (Chief Development Officer) and Mr. Susheel Umesh (Chief Commercial Officer – Emerging Markets). Board changes include recommendations for appointment of independent directors effective August 1, 2026: Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai. The company also indicated that director appointments and re-appointments were approved as part of strengthening the leadership structure.

Investor communication: trading window and earnings call

Biocon filed an exchange intimation under SEBI LODR Regulation 29(1) for the May 7, 2026 board meeting to approve audited Q4 and FY26 results and consider dividend. It also stated that the trading window for company securities was closed from April 1, 2026 to May 9, 2026 (both days inclusive) and would reopen on May 10, 2026. An earnings conference call was scheduled for May 8, 2026 at 09:00 hrs IST via Zoom, with a note that recordings and transcripts would be made available within specified timelines.

Background: earlier FY26 developments around BBL and capital raising

The provided text also references an earlier board meeting on February 12, 2026, where Biocon approved unaudited results for the quarter and nine months ended December 31, 2025. At that meeting, the board granted in-principle approval to acquire the remaining ~2% stake in BBL held by employees and other shareholders, with consideration through preferential allotment of Biocon shares, subject to approvals. The text further mentions a post-period fund raise through QIP of ₹4,150 crore (₹41,500 million) at ₹368.35 per share, partly intended to acquire remaining BBL shares. Separately, it notes completion of a strategic acquisition step on January 5, 2026, including acquisition of 33.38 crore BBL shares and allotment of 17.13 crore Biocon equity shares on a preferential basis to investors, including Mylan Inc.

Operating and segment datapoints cited in the text

Operational datapoints in the provided material include Q3 FY26 consolidated operating revenue of ₹4,173 crore, EBITDA of ₹951 crore, and net profit of ₹144 crore. For the nine months ended December 31, 2025, the segment reporting cited biosimilars revenue of ₹7,675.6 crore (₹76,756 million) and CRDMO revenue of ₹2,702.2 crore (₹27,022 million), with CRDMO profit before tax of ₹285.5 crore (₹2,855 million). The disclosure also lists non-recurring items for the quarter ended December 31, 2025, including BBL acquisition costs of ₹145.5 crore (₹1,455 million) and an inventory provision at BBL of ₹76.2 crore (₹762 million). It also cites a gain of ₹184.2 crore (₹1,842 million) linked to remeasurement of a derivative liability related to the investment in BBL from Mylan Inc.

Snapshot table: key facts and dates disclosed

Market impact: what investors typically track from this set of actions

The immediate market relevance of Biocon’s update lies in three measurable actions: the FY26 profit and revenue print, the dividend recommendation, and the BBL consolidation plan. The dividend size is fixed at ₹0.50 per share in the disclosure, but payment is explicitly subject to shareholder approval at the AGM and the record date process. The BBL transaction is capped at ₹330.73 crore and is structured through preferential issuance, which investors generally evaluate for its impact on ownership and integration. The company also disclosed a targeted completion date of June 30, 2026, which becomes a concrete milestone to track in subsequent filings. The auditor change to S. R. Batliboi & Associates LLP for five years is another governance datapoint that markets tend to watch for continuity in reporting and oversight.

Analysis: why BBL integration and governance steps are central

Biocon’s disclosures place repeated emphasis on making BBL a wholly owned subsidiary, including by acquiring minority holdings and shares held by employees and other shareholders. The text frames this as a move to simplify reporting and governance and to consolidate biosimilar operations under Biocon’s direct control. The preferential issue structure and disclosed parameters (up to 87,92,317 shares at ₹376.16 per share) provide a clear reference for how the transaction is intended to be executed. In parallel, the company’s governance updates, including new statutory auditors and multiple board appointments effective August 2026, suggest an effort to align oversight and leadership with the integration agenda. These are not forward projections but specific steps and dates that will be verifiable through subsequent regulatory updates.

Conclusion: what to watch next

Biocon’s FY26 audited results announcement combined financial performance reporting with a dividend recommendation and a defined plan to increase ownership in BBL by about 2% up to ₹330.73 crore. The next concrete checkpoints disclosed are the May 8, 2026 earnings call, the July 3, 2026 record date, and the August 6, 2026 AGM where the final dividend requires shareholder approval. The company has also set June 30, 2026 as the targeted completion date for the BBL acquisition, subject to required approvals. Investors will likely watch subsequent exchange filings for the final transaction terms and any updates to timelines.